Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)
Niraparib treatment within the German CUP demonstrated favorable safety and tolerability profiles, supporting its effectiveness in a real-world setting for patients with recurrent OC. These findings are consistent with results from clinical trials, further reinforcing the role of niraparib in this patient population.
Authors
- Sabrina Kaiser
- Jolijn Boer (ORCID: https://orcid.org/0009-0009-0873-4686)
- S. Agabejli
- Maja Krajewska (ORCID: https://orcid.org/0000-0003-1285-4786)
- O. Albrecht
- Sabine Heublein (ORCID: https://orcid.org/0000-0002-5326-0186)
- H. Müller-Huesmann
- Ralf Witteler
- Tobias Engler
- Jacek Grabowski (ORCID: https://orcid.org/0000-0001-6204-017X)
- Tjadina Arndt
- Nicolas Moosmann
- Julia Welz (ORCID: https://orcid.org/0000-0003-0102-6053)
- Elena Ioana Braicu
- Bernhard Heinrich (ORCID: https://orcid.org/0000-0002-9334-1335)
- Mustafa Celalettin Ugur
- Cristina Hettwer
- Jalid Sehouli
- Gülten Oskay-Özcelik
- Fabian Kraus
Institutions
- Heidelberg University (DE)
- University Hospital Augsburg (DE)
- University Hospital Heidelberg (DE)
- Humboldt-Universität zu Berlin (DE)
- University Hospital Münster (DE)
- Centrum für Operative Urologie Bremen (DE)
- Cancer Clinic (US)
- Krankenhaus Barmherzige Brüder (DE)
- University Children's Hospital Tübingen (DE)
- Brüderkrankenhaus St. Josef Paderborn (DE)
- Kliniken Essen-Mitte (DE)
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (DE)
- St. Franziskus Hospital (DE)
- University Hospital Ulm (DE)
- University Hospital Carl Gustav Carus (DE)
- Agaplesion Diakonieklinikum Rotenburg (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Archives of Gynecology and Obstetrics
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1007/s00404-025-08295-x
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00